( April 15, 2026, 1:31 PM EDT) -- WASHINGTON, D.C. — The U.S. Supreme Court should let stand a Seventh Circuit U.S. Court of Appeals decision that affirmed a final judgment of $193 million for a qui tam relator who sued Eli Lilly & Co. for reporting falsely deflated drug prices to the government in order to profit off of drug rebate programs because the two questions presented to the high court by the drug manufacturer “are uniquely poor candidates for this Court’s review,” the relator contends in an April 14 opposition brief....